During the past decade, Kirov Research Institute of Hematology and Blood Transfusion conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 10 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 5 clinical trials were completed. i.e. 62.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kirov Research Institute of Hematology and Blood Transfusion" #1 sponsor was "Baxalta now part of Shire" with 7 trials, followed by "Catalyst Biosciences" with 2 trials sponsored, "Federal Research Institute of Pediatric Hematology, Oncology and Immunology" with 2 trials sponsored, "Loxo Oncology, Inc." with 2 trials sponsored and "Octapharma" with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kirov Research Institute of Hematology and Blood Transfusion" #1 collaborator was "Takeda Development Center Americas, Inc." with 3 trials as a collaborator, "Baxalta Innovations GmbH, now part of Shire" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Atlantic Research Group" with 1 trials as a collaborator and "Laboratoire français de Fractionnement et de Biotechnologies" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Kirov Research Institute of Hematology and Blood Transfusion" are "Hemophilia A" (4 trials), "Hemophilia B" (4 trials), "Von Willebrand Disease" (3 trials), "Childhood Acute Lymphoblastic Leukemia" (2 trials) and "Hemophilia A With Inhibitor" (2 trials). Many other conditions were trialed in "Kirov Research Institute of Hematology and Blood Transfusion" in a lesser frequency.

Most popular intervention types in "Kirov Research Institute of Hematology and Blood Transfusion" are "Biological" (12 trials), "Drug" (9 trials), "Other" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Antihemophilic Factor (Recombinant)" (2 trials), "Daunorubicin" (2 trials), "Dexamethasone" (2 trials), "Placebo" (2 trials) and "von Willebrand factor (Recombinant)" (2 trials). Other intervention names were less common.

The vast majority of trials in "Kirov Research Institute of Hematology and Blood Transfusion" are 17 trials for "All" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Kirov Research Institute of Hematology and Blood Transfusion". undefined are not yet recruiting, 6 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Kirov Research Institute of Hematology and Blood Transfusion, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Kirov Research Institute of Hematology and Blood Transfusion, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".